Template:CMV retinitis treatment: Difference between revisions
Ostermayer (talk | contribs) (Marked this version for translation) |
(Convert to AntibioticDose with disease=CMV retinitis for SMW linking) |
||
| Line 6: | Line 6: | ||
<!--T:2--> | <!--T:2--> | ||
*Ganciclovir intraocular implant for 8 months AND | *Ganciclovir intraocular implant for 8 months AND | ||
**Valganciclovir 900mg PO q12hrs x 14 days | **{{AntibioticDose|disease=CMV retinitis|drug=Valganciclovir|dose=900mg PO q12hrs x 14 days then 900mg PO q24hrs x 7 days|context=Severe vision threatening with intraocular implant|population=Adult}} | ||
| Line 12: | Line 12: | ||
<!--T:4--> | <!--T:4--> | ||
*Valganciclovir 900mg PO q12hrs x 21 days | *{{AntibioticDose|disease=CMV retinitis|drug=Valganciclovir|dose=900mg PO q12hrs x 21 days then 900mg PO q24hrs x 7 days|context=Peripheral lesions|population=Adult}} | ||
</translate> | </translate> | ||
Revision as of 01:26, 20 March 2026
Severe Vision Threatening
- Ganciclovir intraocular implant for 8 months AND
- Valganciclovir 900mg PO q12hrs x 14 days then 900mg PO q24hrs x 7 days
Peripheral lesions
- Valganciclovir 900mg PO q12hrs x 21 days then 900mg PO q24hrs x 7 days